
Andreas Rosenwald

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1092603/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	30.7	1,224
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
3	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology, The, 2015, 16, 1111-1122.	10.7	483
4	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 516-532.	16.8	378
5	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 1090-1099.	10.7	315
6	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	27.8	276
7	Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature, 2014, 516, 254-258.	27.8	253
8	IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood, 2015, 126, 1741-1752.	1.4	184
9	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676.	1.4	184
10	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 2016, 128, 1112-1120.	1.4	177
11	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood, 2018, 131, 2060-2064.	1.4	167
12	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, The, 2019, 394, 2271-2281.	13.7	155
13	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
14	Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology, 2019, 37, 2835-2845.	1.6	151
15	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454.	7.1	143
16	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nature Medicine, 2021, 27, 616-619.	30.7	140
17	A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer. Cancer Cell, 2015, 28, 743-757.	16.8	122
18	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016, 128, 1101-1111.	1.4	115

#	Article	IF	CITATIONS
19	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. JAMA Oncology, 2020, 6, 872.	7.1	112
20	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood, 2015, 125, 1137-1145.	1.4	110
21	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood, 2018, 131, 417-420.	1.4	108
22	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nature Communications, 2019, 10, 1459.	12.8	99
23	Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematology,the, 2022, 9, e327-e339.	4.6	98
24	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. Cancer Cell, 2016, 29, 494-507.	16.8	93
25	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia, 2019, 33, 447-456.	7.2	93
26	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 223-234.	10.7	93
27	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	3.6	92
28	MINCR is a MYC-induced IncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	7.1	91
29	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422.	1.4	89
30	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670.	1.4	82
31	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2417-2426.	3.5	81
32	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood, 2015, 125, 124-132.	1.4	79
33	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	3.6	79
34	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nature Communications, 2018, 9, 2378.	12.8	72
35	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 2017, 130, 323-327.	1.4	69
36	<i>TP53</i> mutation and survival in aggressive B cell lymphoma. International Journal of Cancer, 2017, 141, 1381-1388.	5.1	69

#	Article	IF	CITATIONS
37	A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 2000, 27, 52-58.	2.8	67
38	GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica, 2015, 100, 377-384.	3.5	64
39	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood, 2018, 132, 2401-2405.	1.4	64
40	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 2017, 130, 1819-1831.	1.4	62
41	Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 467-489.	2.8	59
42	TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. Nature Communications, 2018, 9, 3115.	12.8	58
43	B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood, 2017, 129, 333-346.	1.4	57
44	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood, 2021, 137, 646-660.	1.4	55
45	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia, 2021, 35, 143-155.	7.2	52
46	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	51
47	USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive Bâ€cell lymphoma. EMBO Molecular Medicine, 2016, 8, 851-862.	6.9	50
48	Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1125-1130.	7.1	49
49	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood, 2018, 132, 1695-1702.	1.4	49
50	Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica, 2018, 103, 116-125.	3.5	48
51	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood, 2020, 136, 2851-2863.	1.4	47
52	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica, 2021, 106, 1943-1956.	3.5	46
53	The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes. Cell Reports, 2019, 27, 3533-3546.e7.	6.4	45
54	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica, 2021, 106, 2682-2693.	3.5	44

#	Article	lF	CITATIONS
55	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. Haematologica, 2016, 101, 1380-1389.	3.5	43
56	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica, 2016, 101, 1002-1009.	3.5	43
57	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. Clinical Cancer Research, 2016, 22, 4341-4349.	7.0	43
58	Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. PLoS ONE, 2014, 9, e109877.	2.5	42
59	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. Journal of Investigative Dermatology, 2018, 138, 1573-1581.	0.7	41
60	IKZF1/3 and CRL4 ^{CRBN} E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica, 2020, 105, e237-e241.	3.5	41
61	Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. , 1998, 22, 114-121.		40
62	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica, 2017, 102, 1413-1423.	3.5	39
63	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood, 2021, 137, 2646-2656.	1.4	39
64	Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. Frontiers in Immunology, 2019, 10, 3090.	4.8	39
65	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica, 2019, 104, e562-e565.	3.5	38
66	Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects. Nature Communications, 2020, 11, 1733.	12.8	38
67	A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?. , 1999, 26, 210-214.		36
68	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Human Pathology, 2014, 45, 2144-2153.	2.0	34
69	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma, 2016, 57, 563-571.	1.3	34
70	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica, 2018, 103, 1182-1190.	3.5	34
71	Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. Leukemia, 2021, 35, 2002-2016.	7.2	34
72	SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma. Modern Pathology, 2018, 31, 505-516.	5.5	31

#	Article	IF	CITATIONS
73	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood, 2018, 131, 226-235.	1.4	31
74	Cognate Nonlytic Interactions between CD8+ T Cells and Breast Cancer Cells Induce Cancer Stem Cell–like Properties. Cancer Research, 2019, 79, 1507-1519.	0.9	31
75	Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Frontiers in Oncology, 2021, 11, 621278.	2.8	31
76	Repression of <scp>SRF</scp> target genes is critical for <scp>M</scp> ycâ€dependent apoptosis of epithelial cells. EMBO Journal, 2015, 34, 1554-1571.	7.8	30
77	Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM. Blood Advances, 2021, 5, 3794-3798.	5.2	30
78	Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood, 2015, 126, 437-444.	1.4	29
79	<i>RSPO2</i> gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut, 2019, 68, 1287-1296.	12.1	29
80	Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 139-159.	2.8	28
81	The clinicopathologic spectrum of mature aggressive B cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 453-466.	2.8	27
82	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood, 2018, 132, 2744-2753.	1.4	27
83	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.	1.8	27
84	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nature Communications, 2021, 12, 5183.	12.8	26
85	Validation of the <scp>MCL</scp> 35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. British Journal of Haematology, 2019, 184, 616-624.	2.5	25
86	The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology, 2019, 94, 1208-1213.	4.1	25
87	Potential influence of concomitant chemotherapy on <scp>CXCR</scp> 4 expression in receptor directed endoradiotherapy. British Journal of Haematology, 2019, 184, 440-443.	2.5	25
88	The exomic landscape of t(14;18)â€negative diffuse follicular lymphoma with 1p36 deletion. British Journal of Haematology, 2018, 180, 391-394.	2.5	24
89	The <scp>MCL</scp> 35 gene expression proliferation assay predicts highâ€risk <scp>MCL</scp> patients in a Norwegian cohort of younger patients given intensive first line therapy. British Journal of Haematology, 2018, 183, 225-234.	2.5	24
90	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. Med, 2021, 2, 1171-1193.e11.	4.4	24

#	Article	IF	CITATIONS
91	Identification of <scp> <i>Candida albicans</i> </scp> regulatory genes governing mucosal infection. Cellular Microbiology, 2018, 20, e12841.	2.1	23
92	CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death and Disease, 2018, 9, 86.	6.3	23
93	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.	3.5	23
94	Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?. Cancer Immunology, Immunotherapy, 2019, 68, 563-575.	4.2	22
95	Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma. Blood, 2019, 133, 377-380.	1.4	22
96	T-cell repertoires in refractory coeliac disease. Gut, 2018, 67, gutjnl-2016-311816.	12.1	21
97	Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes. Journal of Molecular Biology, 2019, 431, 2884-2893.	4.2	21
98	Hexokinase-2 Expression in ¹¹ C-Methionine–Positive, ¹⁸ F-FDG–Negative Multiple Myeloma. Journal of Nuclear Medicine, 2019, 60, 348-352.	5.0	21
99	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. Blood, 2017, 129, 598-608.	1.4	20
100	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. Haematologica, 2020, 105, 2667-2670.	3.5	20
101	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. Blood, 2018, 132, 998-998.	1.4	19
102	Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncology Reports, 2014, 31, 1059-1066.	2.6	18
103	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2021, 8, e267-e277.	4.6	18
104	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. BMC Cancer, 2016, 16, 115.	2.6	17
105	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6039-6053.	7.0	17
106	Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. Oncotarget, 2017, 8, 96732-96737.	1.8	17
107	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. Journal of Clinical Oncology, 2022, 40, 4261-4275.	1.6	17
108	Numerical and Structural Genomic Aberrations Are Reliably Detectable in Tissue Microarrays of Formalin-Fixed Paraffin-Embedded Tumor Samples by Fluorescence In-Situ Hybridization. PLoS ONE, 2014, 9, e95047.	2.5	16

#	Article	IF	CITATIONS
109	Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases. Oncology and Therapy, 2016, 4, 199-210.	2.6	16
110	The identification of patientâ€specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wildâ€ŧype melanomas. Cancer, 2019, 125, 586-600.	4.1	16
111	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal centerâ€derived Bâ€cell lymphomas. Cancer Science, 2020, 111, 749-759.	3.9	16
112	Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids. PLoS Pathogens, 2021, 17, e1009210.	4.7	16
113	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Communications Biology, 2021, 4, 799.	4.4	16
114	Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. Journal of Experimental Medicine, 2021, 218, .	8.5	15
115	Alleleâ€specific <scp>PCR</scp> is a powerful tool for the detection of the <i><scp>MYD</scp>88</i> L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. British Journal of Haematology, 2015, 171, 145-148.	2.5	14
116	Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia, 2022, 36, 760-771.	7.2	14
117	Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials. Blood, 2018, 132, 1622-1622.	1.4	14
118	Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (Velcade®) in Mantle Cell Lymphoma Blood, 2005, 106, 2424-2424.	1.4	14
119	The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells. Haematologica, 2015, 100, e458-e461.	3.5	13
120	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia and Lymphoma, 2016, 57, 717-720.	1.3	13
121	[¹¹ C]Methionine emerges as a new biomarker for tracking active myeloma lesions. British Journal of Haematology, 2018, 181, 701-703.	2.5	13
122	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. Leukemia, 2020, 34, 771-786.	7.2	13
123	⁶⁸ Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine, 2022, 63, 96-99.	5.0	13
124	Prognostic Significance of MYC Single, Double, Triple Hit and MYC-Translocation Partner Status in Diffuse Large B-Cell Lymphoma - a Study By the Lunenburg Lymphoma Biomarker Consortium (LLBC). Blood, 2018, 132, 344-344.	1.4	13
125	Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final results of 116 patients treated in the international ACT-2 phase III trial Journal of Clinical Oncology, 2016, 34, 7500-7500.	1.6	13
126	An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis. Leukemia and Lymphoma, 2017, 58, 1922-1930.	1.3	12

#	Article	IF	CITATIONS
127	Differential expression of long non oding <scp>RNA</scp> s are related to proliferation and histological diversity in follicular lymphomas. British Journal of Haematology, 2019, 184, 373-383.	2.5	12
128	RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica, 2020, 105, 2316-2326.	3.5	12
129	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 133-145.	2.8	12
130	PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group. Blood, 2018, 132, 925-925.	1.4	12
131	Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	6.4	12
132	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2224-2232.	3.5	11
133	Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. Blood, 2020, 135, 181-190.	1.4	11
134	Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica, 2021, 106, 1684-1692.	3.5	11
135	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica, 2021, , .	3.5	11
136	Fluorescence in situ analysis of soft tissue tumor associated genetic alterations in formalin-fixed paraffin-embedded tissue. Pathology Research and Practice, 2014, 210, 804-811.	2.3	10
137	Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathology Research and Practice, 2014, 210, 369-376.	2.3	10
138	Targeting protein kinase C in mantle cell lymphoma. British Journal of Haematology, 2016, 173, 394-403.	2.5	10
139	Novel <i>IGH</i> and <i>MYC</i> Translocation Partners in Diffuse Large B ell Lymphomas. Genes Chromosomes and Cancer, 2016, 55, 932-943.	2.8	10
140	Recurrent Oncogenic JAK and STAT AlterationsÂin Cutaneous CD30-Positive Lymphoproliferative Disorders. Journal of Investigative Dermatology, 2020, 140, 2023-2031.e1.	0.7	10
141	The impact of <scp>SAMHD1</scp> expression and mutation status in mantle cell lymphoma: An analysis of the <scp>MCL</scp> Younger and Elderly trial. International Journal of Cancer, 2021, 148, 150-160.	5.1	10
142	A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 213-225.	7.0	10
143	Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation. Haematologica, 2021, 106, 2654-2666.	3.5	10
144	Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. Histopathology, 2022, 80, 381-396.	2.9	10

#	Article	IF	CITATIONS
145	First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study Journal of Clinical Oncology, 2019, 37, 7503-7503.	1.6	10
146	CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leukemia and Lymphoma, 2022, 63, 468-472.	1.3	10
147	Memory CD4+ T cells lacking expression of CCR7 promote pro-inflammatory cytokine production in patients with diffuse cutaneous systemic sclerosis. European Journal of Dermatology, 2019, 29, 468-476.	0.6	9
148	Doubling rituximab in highâ€risk patients with aggressive Bâ€cell lymphoma â€results of the <scp>DENSE</scp> â€Râ€Mega <scp>CHOEP</scp> trial. British Journal of Haematology, 2019, 184, 760-768.	2.5	9
149	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. British Journal of Haematology, 2022, 196, 116-126.	2.5	9
150	First case of human peritoneal cysticercosis mimicking peritoneal carcinosis: necessity of laparoscopy and histologic assessment for the correct diagnosis. JMM Case Reports, 2017, 4, e005097.	1.3	9
151	Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL). Blood, 2019, 134, 236-236.	1.4	9
152	Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under <i>Viscum album</i> Extracts After Resistance to R-CHOP: A Case Report. Anticancer Research, 2018, 38, 5363-5369.	1.1	8
153	Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Advances, 2020, 4, 4451-4462.	5.2	8
154	Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. Leukemia, 2021, 35, 3589-3593.	7.2	8
155	Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study. Blood, 2010, 116, 993-993.	1.4	8
156	A phase <scp>II</scp> trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre <scp>GOAL</scp> trial. British Journal of Haematology, 2022, 198, 482-491.	2.5	8
157	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. OncoTargets and Therapy, 2014, 7, 1123.	2.0	7
158	Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma. Oncology Letters, 2016, 12, 2942-2947.	1.8	7
159	CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. Journal of the Neurological Sciences, 2018, 385, 96-98.	0.6	7
160	Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines. Cancers, 2020, 12, 455.	3.7	7
161	Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. Cancers, 2021, 13, 315.	3.7	7
162	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of Hematology, 2021, 100, 1537-1546.	1.8	7

#	Article	IF	CITATIONS
163	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. Blood, 2015, 126, 333-333.	1.4	7
164	Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib. Blood, 2016, 128, 3282-3282.	1.4	7
165	Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. Blood Advances, 2021, 5, 4890-4900.	5.2	7
166	Genetic Rearrangements of FOXP1 Are Restricted to a Subset of Agressive B Cell Lymphoma with Extranodal Presentation Blood, 2005, 106, 2837-2837.	1.4	7
167	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations Blood, 2007, 110, 360-360.	1.4	7
168	Targeting CD19 in diffuse large Bâ€cell lymphoma: An expert opinion paper. Hematological Oncology, 2022, 40, 505-517.	1.7	7
169	Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation. PLoS ONE, 2013, 8, e81320.	2.5	6
170	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinibâ€resistant nonâ€nodal leukemic mantle cell lymphoma. European Journal of Haematology, 2020, 104, 352-355.	2.2	6
171	Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or) Tj ETQq1	1 0,78431 1.4	4 _. rgBT /Ove
172	<scp>Epsteinâ€Barrâ€Virus</scp> infection patterns in nodular lymphocyte predominant Hodgkinâ€lymphoma. Histopathology, 2022, , .	2.9	6
173	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines, 2021, 9, 1842.	3.2	6
174	B-cell lymphomas with discordance between pathological features and clinical behavior. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 439-451.	2.8	5
175	Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma—a feasibility study using full slide staining. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 341-349.	2.8	5
176	Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. Blood Cancer Journal, 2019, 9, 67.	6.2	5
177	A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. Haematologica, 2019, 104, e460-e464.	3.5	5
178	The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation. International Journal of Colorectal Disease, 2020, 35, 365-370.	2.2	5
179	<scp>EBER</scp> in situ hybridization in subcutaneous aluminum granulomas/lymphoid hyperplasia: A		
	diagnostic clue to differentiate injectionâ€associated lymphoid hyperplasia from other forms of pseudolymphomas and cutaneous lymphomas. Journal of Cutaneous Pathology, 2021, 48, 625-631.	1.3	5

#	Article	IF	CITATIONS
181	Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients. JID Innovations, 2021, 1, 100034.	2.4	5
182	Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells. Frontiers in Immunology, 2021, 12, 683631.	4.8	5
183	Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation. Cancers, 2021, 13, 5512.	3.7	5
184	Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, 2022, 6, e672.	2.7	5
185	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. Cancers, 2022, 14, 2176.	3.7	5
186	Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment. International Journal of Molecular Sciences, 2021, 22, 2276.	4.1	4
187	Histopathological growth patterns in patients with advanced nodular lymphocyteâ€predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. British Journal of Haematology, 2021, , .	2.5	4
188	The histological and molecular spectrum of lipoblastoma: A case series with identification of three novel gene fusions by targeted RNA-sequencing. Pathology Research and Practice, 2021, 226, 153591.	2.3	4
189	Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma. Blood, 2013, 122, 4253-4253.	1.4	4
190	Multi-drug resistance in B-cell chronic lymphocytic leukemia (B-CLL): A feature of B-CLL sub-sets with poor prognosis genetic alterations?. Leukemia and Lymphoma, 2006, 47, 2263-2264.	1.3	3
191	Next-Generation Sequencing for Lymphomas. Journal of Molecular Diagnostics, 2018, 20, 163-165.	2.8	3
192	Isolated Intraocular Rosai-Dorfman Disease. Ocular Oncology and Pathology, 2019, 5, 418-423.	1.0	3
193	Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. Blood Cancer Journal, 2021, 11, 51.	6.2	3
194	Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. Blood, 2018, 132, 4455-4455.	1.4	3
195	Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the CHSG Phase II Nivahl Trial. Blood, 2020, 136, 6-7.	1.4	3
196	Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma Blood, 2012, 120, 2677-2677.	1.4	3
197	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget, 2016, 7, 38762-38774.	1.8	3
198	NFATc1/αA and Blimp-1 Support the Follicular and Effector Phenotype of Tregs. Frontiers in Immunology, 2021, 12, 791100.	4.8	3

#	Article	IF	CITATIONS
199	DNA microarrays in lymphoid malignancies. Oncology, 2003, 17, 1743-8; discussion 1750, 1755, 1758-9 passim.	0.5	3
200	Acute systemic knockdown of <i>Atg7</i> is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy, 2022, 18, 2880-2893.	9.1	3
201	Mantle cell lymphoma. , 2001, , 154-167.		2
202	Is there still a point for classical cytogenetic banding analysis in the diagnostic work-up of specimens suspicious for lymphoma?. Leukemia and Lymphoma, 2008, 49, 6-7.	1.3	2
203	Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. Annals of Hematology, 2019, 98, 515-517.	1.8	2
204	A Supraclavicular ALK-Positive Anaplastic Large-Cell Lymphoma Initially Misdiagnosed and Yet Successfully Treated with Wide Excision and Adjuvant Chemotherapy: a Case Report. SN Comprehensive Clinical Medicine, 2019, 1, 716-725.	0.6	2
205	The novel <scp><i>KIT</i></scp> exon 11 germline mutation <scp>K558N</scp> is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development. Genes Chromosomes and Cancer, 2021, 60, 827-832.	2.8	2
206	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. Blood, 2012, 120, 679-679.	1.4	2
207	The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl. Blood, 2016, 128, 151-151.	1.4	2
208	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005.	1.4	2
209	Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leukemia and Lymphoma, 2021, 62, 1107-1115.	1.3	2
210	Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53. Frontiers in Cell and Developmental Biology, 2022, 10, 785252.	3.7	2
211	Central nervous system lymphoma. , 2001, , 200-214.		1
212	Dermatopathic lymphadenopathy with Langerhans cell chimerism in graftâ€versusâ€host disease of the skin. European Journal of Haematology, 2017, 99, 582-585.	2.2	1
213	Methotrexate-induced lymphoproliferative disorders: regression matters. Leukemia and Lymphoma, 2018, 59, 1027-1029.	1.3	1
214	A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type. Annals of Hematology, 2021, 100, 2635-2637.	1.8	1
215	PARP14 Is a Novel Therapeutic Target in STAT6 mutant Follicular Lymphoma. Blood, 2018, 132, 2842-2842.	1.4	1
	Dituvinah and Pandamusting for First Ling Treatment of Frail or Elderly Datients with Aggressive		

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma) Tj ETQq0 0 0 rgB4 /Overlock 10 Tf 50

#	Article	IF	CITATIONS
217	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2686-2686.	1.4	1
218	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. Blood, 2016, 128, 4096-4096.	1.4	1
219	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work) Blood, 2004, 104, 415-415.	1.4	1
220	CXCR4 PET/CT Scan Is Superior to FDG PET/CT Scan in Accurately Defining Marginal Zone Lymphoma Nodal and Extranodal Involvement. Blood, 2018, 132, 2881-2881.	1.4	1
221	Inflammation-induced tissue damage mimicking GvHD in human skin models as test-platform for immunotherapeutics. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 429-440.	1.5	1
222	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. Blood, 2021, 138, 1326-1326.	1.4	1
223	Gene expression profiling in lymphoid malignancies. , 2001, , 162-186.		0
224	Hodgkin's lymphoma. , 2001, , 89-110.		0
225	Pathology and cytogenetics. , 2001, , 12-18.		0
226	Follicular lymphoma. , 2001, , 111-125.		0
227	MALT lymphoma and other marginal zone lymphomas. , 2001, , 126-140.		Ο
228	Small lymphocytic lymphoma and its variants. , 2001, , 141-153.		0
229	Diffuse large B-cell lymphoma. , 2001, , 168-181.		0
230	Burkitt's and lymphoblastic lymphomas. , 2001, , 182-199.		0
231	T-cell lymphoma. , 2001, , 215-232.		Ο
232	Cutaneous lymphoma. , 2001, , 233-251.		0
233	Lymphoma in the immunosuppressed. , 2001, , 252-265.		0
234	CLLU1expression: The latest risk predictor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 1665-1666.	1.3	0

#	Article	IF	CITATIONS
235	Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD). Leukemia and Lymphoma, 2021, 62, 2267-2271.	1.3	0
236	Comprehensive Analysis of Homeobox Genes in Hodgkin Lymphoma Cell Lines Identified Dysregulated Expression of HOXB9 Mediated by Constitutive Active ERK5 Signalling Pathway and BMI1 Blood, 2006, 108, 471-471.	1.4	0
237	High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation Blood, 2007, 110, 342-342.	1.4	0
238	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution Blood, 2007, 110, 1585-1585.	1.4	0
239	Spectral Karyotyping and SNP Microarray Analysis Define Uniparental Disomy (UPD) as a Novel Mutational Mechanism in MSI- and CSI-Colorectal Cancers. Analytical Cellular Pathology, 2008, 30, 507-507.	1.4	0
240	Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia Blood, 2009, 114, 3463-3463.	1.4	0
241	Proteasome Inhibition Leads to Dephosphorylation and Downregulation of Protein Expression of Members of the Akt/mTOR Pathway In MCL. Blood, 2010, 116, 4449-4449.	1.4	0
242	Enzastaurin Treatment Affects Multiple Regulatory Pathways at Transcriptome and Cellular Proteome Level of Mantle Cell Lymphoma. Blood, 2010, 116, 2893-2893.	1.4	0
243	Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. Blood, 2010, 116, 52-52.	1.4	0
244	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435.	1.4	0
245	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). Blood, 2011, 118, 2634-2634.	1.4	0
246	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	1.4	0
247	TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial. Blood, 2012, 120, 546-546.	1.4	0
248	Telomere Length in Mantle Cell Lymphoma Blood, 2012, 120, 2509-2509.	1.4	0
249	A Monoclonal IgM Antibody With Specificity To Heat Shock Protein GRP78/BIP Shows Anti- Myeloma Activity In Vitro and In Vivo, Synergy In Combination With Lenalidomide and Safety In a Pilot Phase I Study. Blood, 2013, 122, 3213-3213.	1.4	0
250	Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab. Blood, 2013, 122, 1631-1631.	1.4	0
251	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue – An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	1.4	0
252	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. Blood, 2016, 128, 611-611.	1.4	0

#	Article	IF	CITATIONS
253	ÎFΚΒΙΕ Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. Blood, 2016, 128, 609-609.	1.4	0
254	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. Blood, 2016, 128, 4095-4095.	1.4	0
255	Molecular Features of Germinal Cell Derived B-Cell Lymphomas Using miRNA Signatures. Blood, 2016, 128, 5288-5288.	1.4	0
256	Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance. Blood, 2016, 128, 4512-4512.	1.4	0
257	Clinical Significance of Disseminated Pluripotent Tumor Cell SignatureExpression in the Bone Marrow from Patients with Colorectal Cancer. Journal of Cancer Science & Therapy, 2017, 9, 669-674.	1.7	0
258	Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival Blood, 2018, 132, 3217-3217.	1.4	0
259	FcmR Shapes BCR Signaling in IgM-Positive Leukemia. Blood, 2018, 132, 2620-2620.	1.4	0
260	The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia. Blood, 2018, 132, 5132-5132.	1.4	0
261	The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML. Blood, 2018, 132, 5148-5148.	1.4	0
262	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. Blood, 2018, 132, 4096-4096.	1.4	0
263	A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 2018, 132, 343-343.	1.4	0
264	Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood, 2018, 132, 4188-4188.	1.4	0
265	Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma, Blood, 2019, 134, 4085-4085.	1.4	0
266	Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients. Blood, 2019, 134, 5448-5448.	1.4	0
267	Treatment of mycosis fungoides with brentuximab vedotin: Assessing <scp>CD30</scp> expression by immunohistochemistry and quantitative realâ€time polymerase chain reaction. Journal of Cutaneous Pathology, 2022, 49, 314-317.	1.3	0
268	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). Blood, 2020, 136, 5-6.	1.4	0
269	Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial. Blood, 2020, 136, 33-34.	1.4	0
270	A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior. Acta Neurologica Belgica, 2022, , .	1.1	0